Travere Therapeutics (TVTX) Change in Cash (2011 - 2026)

Travere Therapeutics (TVTX) has 16 years of Change in Cash data on file, last reported at -$14.7 million in Q1 2026.

• Quarterly Change in Cash fell 536.44% year-over-year to -$14.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.5 million (down 11.7% YoY) and the FY2025 annual result came in at $34.5 million, up 9510.03% from the prior year.
• Change in Cash improved to -$14.7 million in Q1 2026, from -$17.9 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $99.7 million in Q1 2023 to a low of -$90.5 million in Q2 2023.
• A 5-year average of -$5.1 million and a median of -$11.0 million in 2024 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2022 — Change in Cash tumbled 681.16% — and 2025, when it surged 768.77%.
• Tracing TVTX's Change in Cash over 5 years: stood at -$89.6 million in 2022, then grew by 3.99% to -$86.1 million in 2023, then soared by 125.71% to $22.1 million in 2024, then slumped by 180.88% to -$17.9 million in 2025, then increased by 18.01% to -$14.7 million in 2026.
• The last three Change in Cash figures came in at -$14.7 million (Q1 2026), -$17.9 million (Q4 2025), and $35.8 million (Q3 2025), per Business Quant data.